New hope for NF1 brain cancer patients as targeted therapy enters phase 2 trial

NCT ID NCT07521657

First seen Apr 13, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tests a drug called mirdametinib, alone or with radiation, in people with a type of brain cancer (high-grade glioma) linked to the genetic condition NF1. The trial has three groups: one for recurrent glioblastoma with NF1 changes, one for newly diagnosed NF1-related glioblastoma, and one for other NF1-related high-grade gliomas. The goal is to see if the drug improves survival or shrinks tumors. About 55 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 (NF1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Childrens of Alabama

    Birmingham, Alabama, 34294, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.